Details for Patent: 8,063,031

Summary for Patent: 8,063,031

Title:	Implants and methods for treating inflammation-mediated conditions of the eye
Abstract:	Methods for treating inflammation-mediated conditions of the eye are described, comprising: implanting into the vitreous of the eye of an individual a bioerodible implant comprising a steroidal anti-inflammatory agent and a bioerodible polymer, wherein the implant delivers the agent to the vitreous in an amount sufficient to reach a concentration equivalent to at least about 0.05 .mu.g/ml dexamethasone within about 48 hours and maintains a concentration equivalent to at least about 0.03 .mu.g/ml dexamethasone for at least about three weeks.
Inventor(s):	Wong; Vernon G. (Menlo Park, CA), Hu; Mae W. L. (Los Altos Hills, CA)
Assignee:	Allergan, Inc. (Irvine, CA)
Application Number:	12/646,522
Patent Claim Types: see list of patent claims	Use; Device;

Drugs Protected by US Patent 8,063,031

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate

International Family Members for US Patent 8,063,031

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	029567
Austria	339185
Australia	2001273166
Australia	2005246995
Australia	7316601
Brazil	0112361
Canada	2414680